MET EXON 14 SKIPPING MUTATION

在大约3%的NSCLC患者中观察到了外显子14突变（Awad等人J Clin Onc 2016报道了28/933），证实在可行时可引起外显子跳跃，并与同时发生的MET扩增有关。临床前模型和个别病例报告以及小规模临床试验（17名接受治疗的患者，Drilon等人，2016年（Suppl；Abdr 108；Asco ID 167889-176））中均报告了对c-met抑制剂crizotinib的反应。需要进行更大的研究，但鼓励在使用Met抑制剂或非标记治疗的试验中注册Met外显子14突变的患者（Paik等人，2015年（Supp；Abdr 8021））。
Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).